Binimetinib (Mektovi)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

From the NCI Drug Dictionary: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2.

Diseases for which it is used

History of changes in FDA indication

History of changes in EMA indication

  • 2018-09-20: Initial authorization

History of changes in Health Canada indication

  • 2021-03-02: Initial notice of compliance in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.

Also known as

  • Code names: ARRY-162, ARRY-438162, MEK162
  • Brand names: Mektovi